Projects per year
Abstract
Leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for some forms of Parkinson's disease. Here we report the discovery and characterization of 2-arylmethyloxy-5-subtitutent-N-arylbenzamides with potent LRRK2 activities exemplified by GSK2578215A which exhibits biochemical IC s of around 10 nM against both wild-type LRRK2 and the G2019S mutant. GSK2578215A exhibits exceptionally high selectivity for LRRK2 across the kinome, substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type LRRK2 and G2019S mutant at a concentration of 0.3-1.0 µM in cells and in mouse spleen and kidney, but not in brain, following intraperitoneal injection of 100 mg/kg.
Original language | English |
---|---|
Pages (from-to) | 5625-5629 |
Number of pages | 5 |
Journal | Bioorganic & Medicinal Chemistry Letters |
Volume | 22 |
Issue number | 17 |
DOIs | |
Publication status | Published - 2012 |
Fingerprint
Dive into the research topics of 'GSK2578215A: a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor'. Together they form a unique fingerprint.Projects
- 1 Finished